Neonatal respiratory distress syndrome (RDS) is a disease that is unique to newborn infants. It is caused by a deficiency of pulmonary surfactant (PS), which is usually ready to be activated around the perinatal period. Until RDS was more clearly understood, it was not known why premature infants died from respiratory failure, although pathology revealed hyaline membranes in the alveoli. Surprisingly, the era of PS replacement therapy began only relatively recently. The first clinical trial investigating neonatal RDS was conducted in 1980. Since then, newborn survival has improved dramatically, which has led to significant advances in the field of neonatology. The present comprehensive review addresses PS, from its discovery to the application of artificial PS in newborns with RDS. It also reviews the history of PS in Korea, including its introduction, various commercial products, present and past research, newborn registries, and health insurance issues. Finally, it describes the inception of the Korean Society of Neonatology and future directions of research and treatment.
INTRODUCTION
In 1959, after Avery and Mead 1 discovered that the pathophysiology of neonatal respiratory distress syndrome (RDS) involved the insufficient production of pulmonary surfactant (PS) in premature infants, "hyaline membrane disease"-the former name of the disease-was replaced by RDS.
Since the description of the pathophysiology of RDS, studies investigating remedies that supplement PS deficiencies in animal models of RDS have been conducted. In 1980, Fujiwara et al. 2 performed treatment via the respiratory tract in 10 pediatric patients with RDS, using Surfactant-TA (Surfacten ® ; Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan), an artificial PS preparation that was reconstituted by adding phospholipids (PLs) to PS extracted from bovine lung. This was the first successful treatment using artificial PS supplementation in humans, and has since resulted in improvement in oxygenation, treatment progress, and prognosis. This therapy has been further developed in the treatment of RDS, which was previously limited to conventional oxygen therapy, artificial ventilation therapy, and other symptomatic therapies. It was the first time that a treatment method of complementing PS with artificial preparations was used, which was a milestone in this field. Since then, this therapy has become the most important and definitive method of neonatal RDS therapy. In fact, it has contributed significantly to the reduction in RDS mortality in the past 30 years, and to the improvement of neonatal, perinatal, and infant mortality rates. 3,4
Surfacten
® was first marketed in Japan in 1986 as the world's first artificial PS replacement therapy for neonatal RDS and, since then, many other similar products have been developed, sold, imported and/or used in Korea. These In Korea, PS replacement therapy for neonatal RDS has been available for 30 years. During this time, the survival rates of very low birth weight infants (VLBWI) and extremely low birth weight infants (ELBWI) have been significantly improved and described in various publications. 5-9 Moreover, the contemporary survival rate is very encouraging, and has reached a level similar to that of advanced countries in Europe and North America. 9
The history of PS research and replacement therapy in foreign countries (as a basic background) and the history of PS replacement therapy in Korea are reviewed from the perspective of the history of its use in Korea, results of treatment, and improvements in prognosis. These narratives are summarized to illustrate the history of RDS, inarguably the most important disease in neonatal care.
HISTORY OF PS AROUND THE WORLD
The history of PS research in the age of pre-clinical trials Laplace was the first to formulate that the external and internal pressures applied to an air bag are inversely proportional to the radius of the air bag and proportional to twice the surface tension (ST). The excess pressure inside a liquid surface is determined by its curvature and tension according to Laplace's equation. A major function of PS is to reduce ST at the air-water interface of the terminal airways, thereby decreasing the tendency for alveolar collapse by Laplace's law. 10 In 1929, Von Neergaard 11 studied PS function in the porcine lung and demonstrated that a lower ST would be useful for the respiratory mechanism. In 1946, Thannhauser et al. 12 showed that the lung contains unusually large amounts of dipalmitoylphosphatidylcholine (DPPC); however, at the time, the association between DPPC and the surface-active properties of the alveolar wall was not known. In 1947, Gruenwald 13 reported that resistance to aeration is caused by ST interfering with the entrance of the air, and surface-active substances were shown to reduce the pressure required for lung aeration. In the 1950s, Clements 14 and Macklin 15 experimentally demonstrated that PS influences the ST in lung volume.
As the pathophysiological mechanism in RDS, the lack of PS in actual clinical practice was first described by Avery , which have been used in the past and are no longer manufactured due to lack of natural surfactant components, particularly the hydrophobic SP-B and C. 25 Synthetic products containing SPs generated through peptide synthesis and recombination technology function similar to the SP-B and C of native human surfactant. 26 These products include Surfaxin ® (generic name as Lucinactant, Discovery Laboratories, Warrington Township, PA, USA), which contains a chemically synthesized SP-B peptide called sinapultide (also known as KL4 peptide) combined with PLs and palmitic acid, and Venticure ® (generic name as rSP-C Surfactant, Byk Gulden, Konstanz, Germany), which contains a recombinant SP-C combined with PLs and palmitic acid. However, clinical trials with these products were discontinued. 27,28
THE HISTORY OF PS IN KOREA PS preparations used in Korea
In Korea, foreign PS preparations have been imported and used since 1991. The composition and characteristics of these preparations are summarized in Table 1 . Since 1991, Surfacten ® has been a component of readjusted natural PS from minced bovine lung extract with DPPC, tripalmitoylglycerol and palmitic acid, and contains SP-B, and -C. Imports have been discontinued since 2018, and are no longer available. Exosurf ® , used from 1991 to 2008, was a synthetic PS of DPPC with 9% hexadecanol and 6% tyloxapol, which was not effective due to lack of SPs, and its production was discontinued in 2008. Curosurf ® , imported from 2003, is a natural PS from minced porcine lung DPPC, subjected to chloroform-methanol extraction, purified by liquid-gel chromatography, and contains SP-B and -C, and is currently in use. Infasurf ® , imported from 2007, had a short period of interruption and was imported again from 2017, is a natural PS from bovine lung lavage extract subjected to chloroform methanol extraction and contains SP-B, and -C. Newfactan ® , a domestic product developed in Korea and used since 1996, has the same components as Surfacten ® .
Efforts and results for the development of PS replacement therapy
The Korean Society of Neonatology has hosted or sponsored numerous symposiums and seminars on PS replacement therapy ( 8 reported changes in the survival rates of VLBWI and ELBWI in Korea before and after the introduction of PS. As shown in Fig. 1 , the introduction of PS in 1991 contributed to improved survival rate, and the survival rates for 2010-2014 were reported to be 84.8% in VLBWI and 69.6% in ELBWI. Chung and Bae 9 compared the survival rates of VLBWI and ELBWI in the KNN data in 2015 with data from western developed countries. Fig. 2 reveals that the levels were similar to those in the United States and Taiwan, which were slightly below those in Japan, Canada, Australia, New Zealand, and Europe.
There have been changes in the ways PS is administered. One focus of current research is the use of less invasive approaches. Tracheal intubation has been performed for PS administration in most premature babies; however, it is now known that positive pressure ventilation should be avoided as much as possible to minimize lung injury. 39 The less invasive surfactant application (LISA) protocol developed by Kribs et al. 40 preserves spontaneous breathing and avoids mechanical ventilation. It allows spontaneous breathing by combining 6/11 https://jkms.org https://doi.org/10.3346/jkms.2019.34.e175
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PS administration and continuous positive airway pressure (CPAP). PS is delivered during
CPAP via a thin catheter. In Korea, some studies have suggested that the early application of CPAP for RDS treatment is effective and can reduce the occurrence of lung injury via the Intubate-SURfactant-Extubation technique. However, there has been little research on LISA. 41,42
The history of insurance benefit for PS replacement therapy in Korea
In 1991, the first imported PS preparations were not initially covered by insurance in Korea.
Insurance started covering single doses in February 1992 and multiple doses in October 2007. 5 Since January 2011, early PS replacement therapy (early prophylactic therapy, which is administered within 2 hours of birth in very preterm infants to prevent RDS, has already been proven to improve the prognosis in other countries) started to be covered by insurance. 5 The criteria for early treatment are as follows: premature babies with a birth weight < 1,250 g or a gestational age < 30 weeks, and a single administration within 2 hours after birth. Recent changes in the standard of insurance benefits for neonatal RDS in Korea are described in Table 4 .
FUTURE DIRECTIONS OF PS RESEARCH IN KOREA
The existing PS formulation is a natural formulation extracted from the lungs of animals (cows or pigs). To avoid the use of preparations of animal origin, research is underway to develop synthetic preparations that are similar to human PS. Bae et al. based on the outcome of this basic work. Evaluating the bioactivity and metabolic fate of peptide-based SP are important for understanding the clearance mechanism of synthetic PS in the lungs. This use of synthetic PS, and not an animal extract, is anticipated to result in mass production and price reduction with significant consequences in clinical application.
As new methods of minimally invasive PS administration are developing, prophylactic PS replacement therapy with LISA may have a benefit over CPAP with rescue administration of PS with LISA. Currently, the indications and methods of LISA are not established. Less invasive methods of PS administration should be studied, including type of PS, dose of PS, indication for multiple PS administrations, and less invasive catheters, in order to achieve maximum performance in patients with RDS.
SUMMARY
The present review provides information regarding the history of RDS treatment in Korea, including a formal definition of the disease, establishment of its pathophysiology, the development of various artificial PSs, the management of a registry network, and the organization of health insurance policies. PS represents the backbone of the exceptional survival of ELBWI. A generational change is occurring in the era of PS, which is anticipated to 8/11 https://jkms.org https://doi.org/10.3346/jkms.2019.34.e175
History of Surfactant Therapy in Korea 2) Chest radiograph: diffuse reticular or granular parenchymal opacities in both lungs, air bronchogram, and radiating appearance. 3) Mechanical ventilation requirements: oxygen concentration of the supply respirator to maintain adequate oxygen partial pressure (50-80 mmHg) exceeds 40% (FiO 2 > 0.4). ※ The use of mechanical ventilator (including invasive and non-invasive methods) should be performed based on medical opinion, taking into account the overall condition of the child (including weight, pulmonary function status, and status of other organs). 2. Early prophylactic therapy for premature infants acknowledges medical care benefits, and patients will be responsible for the full amount of the drug in addition to the accreditation standard. 1) Subject of administration: premature babies with a birth weight < 1,250 g or gestational age < 30 weeks.
2) Method of administration: a single administration within 2 hr after birth. 3. The allowance is exceeded, and the medical care benefit is recognized when the following criteria are met.
Meconium aspiration syndrome: If all of the following conditions are met. 1) There is definitely neonatal respiratory distress.
2) Chest radiograph: there is a characteristic feature of meconium aspiration syndrome (hyperinflammation of both lungs, increased irregular shading around the pulmonary hilum, or diaphragmatic flattening). 3) Mechanical ventilation requirements: oxygen concentration of the supply respirator to maintain adequate oxygen partial pressure (50-80 mmHg) exceeds 40% (FiO 2 > 0.4). 4. Facilities and standards for nursing facility where medication can be administered.
1) Medication should be used under the responsibility of a practicing physician with experience in the treatment of neonatal RDS, and given by skilled workers with experience in neonatal intensive care. 2) Medical equipment required for intensive neonatal care such as incubators, ventilators, blood gas analyzers (one blood gas analyzer, TcpO 2 , and SpO 2 ), and cardiopulmonary monitoring device should be available. 3) In the case of a medical institution with poor 1) and 2) conditions, the patient should be immediately transferred to a medical institution where conditions 1) and 2) are adequate. However, if it is necessary to take urgent measures to resuscitate the child, PS can be administered once only according to the standard of the following clinical standards. 5. Medication should be administered considering the general condition of the child (including weight, pulmonary function status, and status of other organs). PS = pulmonary surfactant, RDS = respiratory distress syndrome.
